Brought to you by 
Aphton acquires igeneon for $74mm in stock
02 Feb 2005
Executive Summary
Aphton Corp. (immunotherapies for cancer and other diseases) has entered into a definitive agreement to acquire privately held igeneon AG (cancer therapeutics). Igeneon shareholders will receive 21.5mm shares of Aphton's stock for all of the company's outstanding equity; based on Aphton's pre-announcement market average price, the deal is valued at about $74mm.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com